Cargando…

Rational Pharmacological Approaches for Cognitive Dysfunction and Depression in Parkinson’s Disease

Parkinson’s disease (PD) is not a single entity but rather a heterogeneous neurodegenerative disorder. The present study aims to conduct a critical systematic review of the literature to describe the main pharmacological strategies to treat cognitive dysfunction and major depressive disorder in PD p...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandoval-Rincón, Maritza, Sáenz-Farret, Michel, Miguel-Puga, Adán, Micheli, Federico, Arias-Carrión, Oscar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379942/
https://www.ncbi.nlm.nih.gov/pubmed/25873910
http://dx.doi.org/10.3389/fneur.2015.00071
_version_ 1782364264096333824
author Sandoval-Rincón, Maritza
Sáenz-Farret, Michel
Miguel-Puga, Adán
Micheli, Federico
Arias-Carrión, Oscar
author_facet Sandoval-Rincón, Maritza
Sáenz-Farret, Michel
Miguel-Puga, Adán
Micheli, Federico
Arias-Carrión, Oscar
author_sort Sandoval-Rincón, Maritza
collection PubMed
description Parkinson’s disease (PD) is not a single entity but rather a heterogeneous neurodegenerative disorder. The present study aims to conduct a critical systematic review of the literature to describe the main pharmacological strategies to treat cognitive dysfunction and major depressive disorder in PD patients. We performed a search of articles cited in PubMed from 2004 to 2014 using the following MeSH terms (Medical subject headings) “Parkinson disease”; “Delirium,” “Dementia,” “Amnestic,” “Cognitive disorders,” and “Parkinson disease”; “depression,” “major depressive disorder,” “drug therapy.” We found a total of 71 studies related to pharmacological treatment in cognitive dysfunction and 279 studies for pharmacological treatment in major depressive disorder. After fulfillment of all the inclusion and exclusion criteria, 13 articles remained for cognitive dysfunction and 11 for major depressive disorder, which are presented and discussed in this study. Further research into non-motor symptoms of PD may provide insights into mechanisms of neurodegeneration, and provide better quality of life by using rational drugs.
format Online
Article
Text
id pubmed-4379942
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-43799422015-04-13 Rational Pharmacological Approaches for Cognitive Dysfunction and Depression in Parkinson’s Disease Sandoval-Rincón, Maritza Sáenz-Farret, Michel Miguel-Puga, Adán Micheli, Federico Arias-Carrión, Oscar Front Neurol Neuroscience Parkinson’s disease (PD) is not a single entity but rather a heterogeneous neurodegenerative disorder. The present study aims to conduct a critical systematic review of the literature to describe the main pharmacological strategies to treat cognitive dysfunction and major depressive disorder in PD patients. We performed a search of articles cited in PubMed from 2004 to 2014 using the following MeSH terms (Medical subject headings) “Parkinson disease”; “Delirium,” “Dementia,” “Amnestic,” “Cognitive disorders,” and “Parkinson disease”; “depression,” “major depressive disorder,” “drug therapy.” We found a total of 71 studies related to pharmacological treatment in cognitive dysfunction and 279 studies for pharmacological treatment in major depressive disorder. After fulfillment of all the inclusion and exclusion criteria, 13 articles remained for cognitive dysfunction and 11 for major depressive disorder, which are presented and discussed in this study. Further research into non-motor symptoms of PD may provide insights into mechanisms of neurodegeneration, and provide better quality of life by using rational drugs. Frontiers Media S.A. 2015-03-31 /pmc/articles/PMC4379942/ /pubmed/25873910 http://dx.doi.org/10.3389/fneur.2015.00071 Text en Copyright © 2015 Sandoval-Rincón, Sáenz-Farret, Miguel-Puga, Micheli and Arias-Carrión. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Sandoval-Rincón, Maritza
Sáenz-Farret, Michel
Miguel-Puga, Adán
Micheli, Federico
Arias-Carrión, Oscar
Rational Pharmacological Approaches for Cognitive Dysfunction and Depression in Parkinson’s Disease
title Rational Pharmacological Approaches for Cognitive Dysfunction and Depression in Parkinson’s Disease
title_full Rational Pharmacological Approaches for Cognitive Dysfunction and Depression in Parkinson’s Disease
title_fullStr Rational Pharmacological Approaches for Cognitive Dysfunction and Depression in Parkinson’s Disease
title_full_unstemmed Rational Pharmacological Approaches for Cognitive Dysfunction and Depression in Parkinson’s Disease
title_short Rational Pharmacological Approaches for Cognitive Dysfunction and Depression in Parkinson’s Disease
title_sort rational pharmacological approaches for cognitive dysfunction and depression in parkinson’s disease
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379942/
https://www.ncbi.nlm.nih.gov/pubmed/25873910
http://dx.doi.org/10.3389/fneur.2015.00071
work_keys_str_mv AT sandovalrinconmaritza rationalpharmacologicalapproachesforcognitivedysfunctionanddepressioninparkinsonsdisease
AT saenzfarretmichel rationalpharmacologicalapproachesforcognitivedysfunctionanddepressioninparkinsonsdisease
AT miguelpugaadan rationalpharmacologicalapproachesforcognitivedysfunctionanddepressioninparkinsonsdisease
AT michelifederico rationalpharmacologicalapproachesforcognitivedysfunctionanddepressioninparkinsonsdisease
AT ariascarrionoscar rationalpharmacologicalapproachesforcognitivedysfunctionanddepressioninparkinsonsdisease